Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)

Next Previous
Trial Profile

Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1323495 (Primary) ; Dabigatran etexilate; Rosuvastatin
  • Indications Chronic obstructive pulmonary disease; Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 28 Sep 2020 Status changed from active, no longer recruiting to completed.
  • 27 Aug 2020 Status changed from recruiting to active, no longer recruiting.
  • 15 Jul 2020 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top